Vaccine efficacy of CoronaVac against COVID-19 in children in Brazil during the Omicron period
Frenck, RW et al. Safety, immunogenicity and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N.Engl. J.Med. 385239-250 (2021).
Walter, EB et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years old. N.Engl. J.Med. 38635–46 (2022).
Center for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). (2020). Available at: https://emergency.cdc.gov/han/2020/han00432.asp. (Accessed: May 14, 2020).
Stein, M. et al. Project report The burden of COVID-19 in children and its prevention through vaccination: a joint statement by the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. Vaccines ten81 (2022).
Ministry of Saude do Brasil. Technical Note Noh6/2022-Secovid/Gab/Secovid/Ms.. (2022).
Jara, A. et al. Efficacy of an inactivated vaccine against SARS-CoV-2 in children and adolescents: a large-scale observational study. SSRN (2022).
Jara, A. et al. Efficacy of CoronaVac in children 3-5 years old during the omicron SARS-CoV-2 outbreak. Nat. Med. 281377-1380 (2022).
Florentino, PTV et al. Vaccine efficacy of two-dose BNT162b2 over time against symptomatic COVID-19 infection and severe cases in adolescents: negatively designed case-control studies in Brazil and Scotland. The Lancet Infectious Diseases. 1–23 (2022).
Andrews, N et al. Efficacy of the Covid-19 vaccine against the Omicron variant (B.1.1.529). N.Engl. J.Med. 3861532-1546 (2022).
Buchan, SA, Nguyen, L., Wilson, SE, Kitchen, SA, and Kwong, J. Vaccine efficacy of BNT162b2 versus Omicron and Delta findings in adolescents. medRxiv 2022.04.07.22273319 (2022).
Veneti, L. et al. Vaccine efficacy with BNT162b2 vaccine (Comirnaty, Pfizer-BioNTtech) against reported SARS-CoV-2 delta and omicron infection in adolescents, Norway, August 2021 to January 2022. SSRN electron. J 21–11 (2022).
Dorabawila, V. et al. Efficacy of the BNT162b2 vaccine in children 5-11 and 12-17 years old in New York after the emergence of the Omicron variant. medRxiv 2022.02.25.22271454 (2022).
Sacco, C. et al. Articles Efficacy of the BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis from January to April 2022. Lancet 21–7 (2022).
Vandenbroucke, J. & Pearce, N. Negative test design differences and commonalities with other case-control studies with “other patient” controls. Epidemiology 30838–844 (2019).
Dawood, FS, Porucznik, CA, Veguilla, V. & Al, E. Incidence rate, household infection risk, and clinical features of SARS-CoV-2 infection in children and adults in the Utah and New York City, New York. Jama Pediatrics 17659–67 (2022).
Mensah, AA et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January 2020 and July 2021, in England. Lancet Child Teenager. Health 6384–392 (2022).
Lipsitch, M., Goldstein, E., Ray, GT & Fireman, B. Susceptible subject exhaustion bias in studies of influenza vaccine decline: how to ensure robust results. Epidemiol. Infect. 147e306 (2019).
Katikireddi, SV et al. Protection of the two-dose ChAdOx1 nCoV-19 vaccine against COVID-19-related hospitalizations and deaths over time: a population-based retrospective cohort study in Scotland and Brazil. Lancet 39925–35 (2022).
Cerqueira-Silva, T. et al. Vaccine efficacy of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Medium. 28838–843 (2022).
Cerqueira-Silva, T. et al. Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet infect. Say. 221–2 (2022).
Cerqueira-Silva, T. et al. Efficacy of CoronaVac, ChAdOx1 nCoV-19, BNT162b2 and Ad26.COV2.S in people with previous SARS-CoV-2 infection in Brazil: a test-negative case-control study. Lancet infect. Say. 22791–801 (2022).
Vandenbroucke, JP, Brickley, EB, Vandenbroucke-Grauls, CMJE & Pearce, N. A test-negative design with additional population controls can be used to rapidly investigate the causes of the SARS-COV-2 outbreak. Epidemiology 31836–843 (2020).
Fiocruz. GISAID. Rede Genomica (2020). Available at: http://www.genomahcov.fiocruz.br/#. (Accessed: May 15, 2022)
Allik, M. et al. Small Area Deprivation Measure for Brazil: Data Documentation. University of Glasgow (2020). Available at: https://researchdata.gla.ac.uk/980/. (Accessed: May 15, 2020).
Vienna, AR Core Team. A: A language and environment for statistical computing. R foundation for statistical computing; (2021).
Wickham, H. et al. Welcome to the Tidyverse Tidyverse Package. J. Open Source Software. 41–6 (2019).
van Buuren, S. & Groothuis-Oudshoorn, K. mouse: multivariate imputation by chained equations in R. J. Stat. Software 451–67 (2011).
Firth, D. “Reducing the Bias of Maximum Likelihood Estimates.”. Biometrics 82667 (1995).
Benchimol, EI et al. The study report produced using the RECORD (Observational Routinely-collected health data) declaration. PLoS Med. 121–22 (2015).